CEACAM5 and pancreatic adenocarcinoma: A recent study was conducted to assess the potential roles of ctDNA in early relapse detection and disease status monitoring in early-stage pancreatic adenocarcinoma (PDAC) prediction, as well as evaluating other tumor markers such as carcinoembryonic antigen (CEA) and cancer antigen 19–9 (CA 19–9).